Anatara Lifesciences receives European patent for GaRP product

Anatara Lifesciences (ASX:ANR) has been granted a European patent for its Gastrointestinal ReProgramming product (GaRP) by the European Patent Office (EPO). The patent provides protection until March 2039 and is being validated in 19 major European countries plus the United Kingdom. GaRP is designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD, and has the potential to be a disease-modifying treatment.

Executive Commentary on European Patent Grant

Anatara's Executive Chair Dr. David Brookes expressed his satisfaction with the patent grant, stating, 'We are very pleased to see the uniqueness of GaRP being confirmed with this patent grant. The mechanism of action of GaRP is based on ingredients designed to restore and maintain the gastrointestinal tract lining and dynamics, using sophisticated coatings and combinations. This potentially has broad health indications and we look forward to the progress of our current Phase // GaRP-IBS trial in establishing efficacy data. A successful conclusion of the Irritable Bowel Syndrome (IBS) clinical trial is obviously a key consideration for market differentiation and commercialisation.'

Summary of European Patent Grant and Outlook

Anatara Lifesciences has secured a European patent for its GaRP product, expanding its intellectual property protection. The patent, valid until March 2039 and being validated in 19 major European countries plus the United Kingdom, signifies a significant milestone for the company. GaRP, designed to assist restoration and maintenance of the gastrointestinal tract lining as a barrier and assist the homeostasis of the microbiome, has the potential to positively impact a substantial proportion of the population suffering from digestive disorders, including irritable bowel syndrome (IBS). With the commercial opportunity for non-prescription products for gastrointestinal disorders and IBS estimated at US$8 billion in the USA alone, Anatara is well-positioned to address the clear unmet need in the market. The company's focus on building a pipeline of human health products with a particular emphasis on conditions involving the complexity of the gastrointestinal tract reflects its commitment to delivering real outcomes for patients and strong value for its shareholders.